Under construction – not a live service
Sign in
Taking people in FranceNo phase

Studying why some blood disorder patients respond poorly to standard treatment

Looks at gene mutations and blood markers in adults with polycythemia vera or thrombocythemia.

Key facts

Who runs it
University Hospital, Angers
Where
Angers, Brest, Nantes, Poitiers, Rennes, and Tours, FranceSee the 6 sites
Trial code
Registry title
Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
Status
Recruiting
People taking part
120 people, planned
Started
17 May 2023
Expected to end
17 Feb 2032
Type of study
Observational
Treatments tested
  • Next-generation sequencing
Record updated
6 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with polycythemia vera, essential thrombocythemia or pre-myelofibrosis who need first-line treatment with hydroxyurea or pegylated interferon.

Age
18 years and older
Sex
All sexes can join.
Disease stage
Polycythemia vera, essential thrombocythemia or pre-myelofibrosis, with an indication for first-line treatment with hydroxyurea or pegylated interferon.
Earlier treatment
People who have already had treatment cannot join.

Main reasons for not taking part

  • Previous treatment
  • Another ongoing cancer, including overt myelofibrosis
  • Treatment with phlebotomy alone, ruxolitinib, anagrelide or pipobroman

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Adults with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis
  • Indication for first-line treatment with hydroxyurea or pegylated interferon
  • Consent to participate
  • Affiliated to social security

Who cannot take part

  • Previous treatment
  • Other on-going malignancy, including overt myelofibrosis
  • Other treatment such as phlebotomy solely, ruxolitinib, anagrelide, or pipobroman

Where in France

  • CHU AngersAngers, FranceContact: CORENTIN ORVAIN, DOCTORTaking people
  • Chu BrestBrest, FranceContact: JEAN-CHRISTOPHE IANOTTOTaking people
  • CHU NantesNantes, FranceContact: VIVIANE DUBRUILLETaking people
  • CHU PoitiersPoitiers, FranceContact: Jose-Miguel TORREGROSA-DIAZTaking people
  • CHU RennesRennes, FranceContact: MARC BERNARDTaking people
  • CHU ToursTours, FranceContact: ANTOINE MACHETTaking people

About the trial

What the trial wants to find out

First-line treatment for patients with polycythemia vera, essential thrombocythemia, and pre-myelofibrosis is based on hydroxyurea or pegylated interferon. The objective of treatment is to prevent thrombotic complications and leukemic transformation. Despite overall good response rates, some patients do not respond to treatment and others lose their response over time. Both situations are associated with worse survival and there are to date no clear predictive factors for response although the existence of additional mutations seems unfavorable.

Read full original descriptionShow less

In this exploratory study, we hypothesize that biological factors at diagnosis are associated with hematological response at 12 months. We will more specifically study the association between mutational profile, assessed by next-generation sequencing, and cytokine profile with hematological response.

This study will help in identifying patients who will not respond to hydroxyurea or pegylated interferon and give the opportunity to try other treatments upfront, in the perspective of precision medicine. On the basic science side, this study will help in understanding the molecular and immunological factors involved in resistance to treatment.

Treatments tested

  • Next-generation sequencing

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
Plain-language title
Studying why some blood disorder patients respond poorly to standard treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 March 2026